Our Science
Ourfoundationalworkinhealthyagingharnessesthemicrobiotaoffruitsandvegetablestoaddressthemostcommonage-relatedinflammatorydisorders.
Bone density loss is a natural result of the aging process. Our discoveries in bone health have yielded a safe, clinically-validated way to improve bone density, which has the potential to help reduce the risk of conditions like osteoporosis.
Bone Health
Rheumatoid Arthritis
Psoriatic Arthritis
Cellular health
Menopause
Our Scientific
Process
Microbe Isolation
Using our novel scientific method, our premier team of scientists isolates the microbes naturally found on fruits, vegetables, and fermented foods and sequences each isolate’s full genome for our microbial library.
- Over 5000 microbial isolates
- Over 16M genes
- Over 7M biosynthetic clusters
Days
Genomic Sequencing
With deep sequencing technology, we sequence the full genome of every isolate in our microbial library.
- Over 1,400 high-quality microbial genomes
Days
In silico Predictions
We leverage AI to mine our proprietary genomic databases to accurately and precisely identify the most promising immunomodulatory candidates to advance to in vitro validation.
- Thousands of strains identified
Days
DMA™ Product Formulation
Selected strains are developed into Defined Microbial Assemblages (DMA™), combinations of bacteria, fungi, and prebiotic plant fibers that synergize to produce stronger anti-inflammatory responses than the sum of their parts.
- Dozens of strains selected
1-2 months
Preclinical testing
Lead candidate DMA™ medical food products are rigorously evaluated using gold-standard preclinical disease models for safety and efficacy.
- 1-5 DMA™ candidates
3-6 months
Clinical validation
We employ randomized, double-blind, placebo-controlled human clinical food trials to validate our DMA™ medical foods. These trials are designed by world-renowned physicians, using the same standards as pharmaceutical trials.
- 1 DMA™
6-24 months
Advisors
WecontinuetoexplorenovelapplicationsofMicroscopeTechnology™
SBD111
Clinically validated to slow bone loss via the targeting of osteoclastic activity (clinical study pending publication & peer review)
SBD121
Being developed to address the needs of rheumatoid arthritis
SBDXXX
Being developed to address the needs of psoriatic arthritis
SBDXXX
Being developed to address the needs of cellular aging
ScientificPublications
Food and Chemical Toxicology – 2024
Food safety assessment and 28-day toxicity study of the synbiotic Medical Food consortium SBD121.
Easson DD, Murphy VA, Ballok AE, Soto-Giron MJ, Miller KJ, Charbonneau MR, Schott EM, Greene T, Rodricks J, Toledo GV
Gut Microbes – 2023
The edible plant microbiome: evidence for the occurrence of fruit and vegetable bacteria in the human gut
Wicaksono W, Cernava T, Wassermann B, Abdelfattah A, Soto-Giron M, Toledo G, Virtanen S, Knip M, Hyöty H, Berg G
Clinical trial: SBD121, a Synbiotic Medical Food for RA Management – 2023
The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid arthritis (RA).
Journal of Microbiology & Experimentation – 2023
Randomized clinical trial to test the safety and tolerability of SBD111, an optimized synbiotic medical food combination designed for the dietary management of the metabolic processes underlying osteopenia and osteoporosis.
Sahni S, Schott E, Caroll D, Soto-Giron M, Corbett S, Toledo G, Kiel D.
Nature Biopharma Dealmakers – 2022
Managing inflammatory diseases and aging with edible plant microbes
Clinical trial: Food Trial Evaluating the Efficacy of SBD111 Versus Placebo for the Clinical Dietary Management of the Metabolic Processes of Osteopenia – 2022
The aim of the trial is to determine if the SYNBIOTIC (prebiotic and probiotic), provided twice daily (capsule) will help support skeletal health in otherwise healthy postmenopausal women in the early years postmenopause (1-6 years post last menstruation) over a 12-month period.
Am Journal Physiol Endocrinol Metab – 2022
Development of a synbiotic that protects against ovariectomy induced trabecular bone loss.
Lawenius L, Gustafsson KL, Wu J, Nilsson KH, Movérare-Skrtic S, Schott EM, Soto-Girón MJ, Toledo GV, Sjögren K, Ohlsson C.
Food and Chemical Toxicology – 2022
Food safety assessment and toxicity study of the synbiotic consortium SBD111.
Easson DD, Murphy VA, Ballok AE, Soto-Giron MJ, Schott EM, Rodricks J, Toledo GV
Scientific Reports – 2021
The Edible Plant Microbiome represents a diverse genetic reservoir with functional potential in the human host
Soto-Giron MJ, Kim JN, Schott E, Tahmin C, Ishoey T, Mincer TJ, DeWalt J, Toledo G
Nutrients – 2020
Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Palacios T, Vitetta L, Coulson S, Madigan CD, Lam YY, Manuel R, Briskey D, Hendy C, Kim JN, Ishoey T, Soto-Giron MJ, Schott EM, Toledo G, Caterson ID